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ABSTRACT 
The acute influences of stress levels of the insulin counter- 
regulatory hormones cortisol, epinephrine, and glucagon on protein 
metabolism is not established. The mechanism by which cortisol 
induces hyperaminoacidemia also merits examination. Five post- 
absorptive normal subjects were each studied twice, during a six 
2 2 
hour infusion of cortisol (5 mg/m /hr) and of cortisol (5 mg/m /hr), 
2 
epinephrine (1.2 ug/m /min) and glucagon (3 ng/kg/min) together 
in doses designed to simulate changes observed in severe stress. 
To allow calculation of protein kinetics, stable isotopically 
13 
labelled 1- C-leucine was infused continuously as a tracer and 
assayed for using gas chromatography-mass spectrometry. 
During cortisol infusion, branched chain amino acid (BCAA) 
levels rose by 23%. Levels of other amino acids were unchanged. 
There was no significant change between the pre-infusion and end 
of infusion rates of leucine flux, oxidation, or synthesis to 
protein, but the metabolic clearance rate of leucine fell signif¬ 
icantly (30%). The lack of change in leucine enrichment over the 
course of the study suggests that the rate of appearance, R , of 
3 
leucine, was unchanged and the rate of disappearance of leucine, 
R^, fell. Non-steady state calculations showed a tendency for R^ 
to decrease slightly, and for R^ to decrease to a greater extent. 
In response to cortisol infusion, plasma cortisol levels doubled, 
epinephrine, glucagon and insulin levels remained unchanged, and 
plasma glucose levels rose mildly (13%). 
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Infusion of cortisol, epinephrine, and glucagon together pro¬ 
duced a marked decrease in BCAA levels (42%) as well as of most 
other amino acid levels measured. During the last 45 minutes of 
study plasma alanine levels rose significantly (20%). Preliminary 
isotope enrichment data suggest that leucine flux fell somewhat 
and leucine metabolic clearance rate rose during the study. Cort¬ 
isol, epinephrine, and glucagon rose to levels mimicking those 
seen in severe stress. There was a 200% rise in insulin levels, 
and a 200% rise in plasma glucose levels. 
It is concluded that: 1. Levels of cortisol acutely simulating 
stress result in elevated levels of BCAAs due to a fall in the meta¬ 
bolic clearance rate of leucine. There is a tendency for the 
of leucine to decrease more than does the R of leucine. Hypo- 
a 
insulinemia is known to produce changes similar to the ones demon¬ 
strated here, thus, although insulin levels remain stable during 
the study, an inhibitory effect of steroids on the actions of insulin 
is suggested to account for the results. 2. Triple hormone infu¬ 
sion results in a marked decrease in circulating amino acid levels. 
This hypoaminoacidemic effect, opposite in direction to the hyper- 
aminoacidemic effect of cortisol alone, is in marked contrast to 
the synergistic effects of the three hormones to produce hyperglycemia 
of greater magnitude but similar in direction to the glucose 
intolerance induced by cortisol alone. The hypoaminoacidemia is 
possibly due either to the actions of insulin or to a combined 
effect of insulin and epinephrine in stress-simulating levels. 
' 
3 
CONSIDERATION OF PROTEIN BALANCE 
Maintenance of protein balance is a dynamic process. The 
two organs (1) primarily involved in this process are muscle and 
liver. Muscle contains greater than fifty percent of the total 
body pool of free amino acids, and liver contains the urea cycle 
enzymes. 
Typically, a 12 to 14 hour "overnight fast" (1), which is 
defined as the post-absorptive state, results in a net release 
of amino acids (primarily alanine and glutamine) from muscle 
tissue and an uptake across the splanchnic bed (again primarily 
of alanine and glutamine; the former into the liver, the latter 
into the gut). Interestingly, alanine constitutes only 7-10% of 
protein amino acid. Investigation (2) of the possible origin of 
the remaining large amount of alanine produced led to postulation 
of the glucose-alanine cycle. 
Substrate availability (3) is an important regulator of 
hepatic gluconeogenesis; amino acids are quantitatively impor¬ 
tant gluconeogenetic precursors (4), and skeletal muscle is a 
major potential source of amino acids, thus the control of muscle 
protein breakdown and synthesis has important implications for 
an understanding of fuel balance in the intact mammal. 
Leucine has been postulated to play an important role in 
the regulation of protein turnover (5). The branched chain 
amino acids are the only essential amino acids which are oxi¬ 
dized mainly extrahepatically (6), principally by skeletal 
muscle, (7,8,9). In conditions of severe stress, branched chain 
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amino acid (BCAA) oxidation is accelerated (10), which provides 
energy to muscle, and amino groups for transamination of glucose- 
derived pyruvate for alanine and glutamine synthesis (5). These 
products are used by the liver and kidneys as substrates for 
gluconeogenesis (11,12). 
It was postulated (5) that depletion of some or all compon¬ 
ents of the BCAA pool by oxidation could "serve as a signal to 
accelerate the catabolism of muscle proteins and/or inhibit their 
rate of synthesis (5)." Studies (5) examining radioactive tracer 
incorporation into hemidiaphragm proteins in the presence of 
various combinations of BCAAs with inhibitors showed that leucine 
increased protein labelling, and that RNA synthesis was not 
necessary for enhanced labelling, nor was protein synthesis re¬ 
quired for initiation of the effect. The data strongly suggested 
that leucine promoted protein synthesis, and inhibited protein 
breakdown. Another study (13) agreed with this result, concluding 
that leucine alone, or isoleucine and valine together, inhibited 
rat diaphragm protein degradation and promoted synthesis of 
protein. 
Interestingly, a less decisive role for leucine has been 
demonstrated in rat hearts (14,15), where no significant effect 
on protein synthesis or degradation was found. 
An overview of the theory and methods for studying protein 
metabolism in, vivo is useful, as much work has been done using 
a variety of techniques. 
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THEORY AND METHODS OF PROTEIN TURNOVER DETERMINATION 
Amino acid turnover can be defined as the rate at which 
an amino acid is renewed, either by synthesis and breakdown, 
or by exchange with the same material in another compartment. 
Because exchange of each amino acid with protein is not inde¬ 
pendent of that of other amino acids, the fractional rate of 
turnover of an essential amino acid may be taken to represent 
that of the whole protein. The equation used to calculate flux 
in an equilibrium system is 
Q=I+B+N=E+Z+M, where 
Q = is flux, the next three terms represent sources of entry of 
amino acid into the pool, where I = amino acid intake, B = amino 
acid derived from protein breakdown, N = cle novo synthesis of 
non-essential amino acids, and the last three terms represent 
possible exits for the amino acids, where E = oxidized amino acid, 
Z = amino acid synthesized to protein, and M is amino acid metab¬ 
olized through other pathways (assumed to be engligible compared 
with E and Z). Thus for the essential amino acid leucine the 
equation may be simplified such that leucine flux is equal to total 
synthesis rate plus leucine oxidation rate, rates which are 
measured in our study as described below. 
A variety of isotopes have been used in several ways to 
measure protein turnover in mammalian systems. These isotopes 
can be given either by constant infusion or as a single dose. 
In the case of constant infusion, the specific activity of the 
tracer will reach a plateau, thus sampling at only a few time 
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points is required to determine fairly accurate values. It is 
also possible to assay for the tracer by end product analysis, 
as long as the end product is formed only from the tracer, and 
only from tracer available in the metabolic pool. Compartmental 
analysis can be performed in such situations. 
Stochastic analysis can be done on constantly infused tracers, 
or on isotopes given as a single dose. This method assumes that 
flux is best estimated by disposal rate of labelled tracer. This 
rate can be measured in blood or in urine. Problems arise with 
either method; plasma levels of tracer may not equal intracel¬ 
lular pool levels, and the precursor pool for urinary urea forma¬ 
tion, for example, does not necessarily represent the intracellular 
pool for protein synthesis in every organ. 
Potential sources of error in calculations done by the 
above methods are due in large part to assumptions made about 
the models. It is assumed that tracer metabolism reflects that 
of the amino acid pool in general. A single homogeneous well- 
mixed precursor pool for protein synthesis is assumed, but in fact 
is very unlikely to exist. Tracer concentrations are undoubtedly 
higher in the measured extracellular pool than in the unmeasured 
intracellular pool, where protein breakdown dilutes the tracer. 
Re-entry of label is assumed not to occur; in other words, once 
a protein has been labelled with an amino acid it is assumed 
not to release that amino acid for reuse. This difficulty is 
minimized by studies of short duration. The assumption that 
routes of amino acid disposal other than synthesis or oxidation 
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are not available is true only for selected amino acids; others 
can undergo one of many metabolic fates including interconversion, 
perhaps even of the label itself, if not chosen carefully. Non¬ 
steady state is an important consideration. If the protein pool 
is changing in size, this will be reflected adequately in the 
measurements. However, changes in the amino acid pool can seriously 
effect measurements. Thus it is important, in the case of a con¬ 
stant infusion, to look for a plateau, which indicates little change 
in pool size. Single dose infusions are not affected by pool size; 
the area under the curve used to calculate the value of the inte¬ 
gral remains unchanged. 
Classically (16), nitrogen metabolism was monitored by nitro¬ 
gen balance techniques involving monitoring of urinary nitrogen 
excretion and nitrogenous intake. Other studies examined blood 
NPN fractions from normal (17), nephrectomized (18), and eviscerated 
(19) animals. Individual organs were analyzed before and after 
experimental manipulation (20), and techniques were developed for 
studying portions of organs under in vitro conditions (16). 
The first quantitative study (21) of protein turnover in 
humans employed ^N-glycine, and involved urinary excretion 
measurement for 72 hours. In the intervening years, numerous 
studies employing nitrogen-15 as a tracer and measuring urinary 
isotope excretion over time have been conducted. Conclusions 
which can be drawn from this work are as follows (22): 1. The 
initial part of the excretion curve is unlikely to provide 
accurate conclusions. 2. Although in theory the most appropriate 
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method, analysis of the entire excretion curve is in practice 
quite difficult. 3. Calculations using cumulative excretion of 
isotope in which attempts are made to unify progressively chang¬ 
ing rates of decay (of which there are usually at least three 
rates) into one slope are unsatisfactory. 4. Calculations using 
cumulative excretion of nitrogen-15 48 hours after a single dose 
are a reasonable compromise. 
Stochastic methods are preferred for measuring total protein 
turnover with nitrogen-15 as a tracer. Two major assumptions 
in this case are that the tracer represents the behavior of the 
total amino-nitrogen, and that the precursor pool for end-product 
and for protein synthesis are the same, as well as the assumption 
that end product can come from this pool only. Both single-dose 
and continuous infusions can be used with this method, as long 
as the limitations of each one are kept in mind. End products 
of nitrogen-15 studies can include urea, ammonia or the labelled 
amino acid itself. Urea pools are larger, and turn over slowly, 
whereas ammonia is easier to isolate, has a smaller pool, and 
a more rapid turnover rate. Yet variability of this product is 
great with intermittent doses of label, and there is a signifi¬ 
cant dose effect. 
15 
Various tracers besides N-glycine can be employed. 
Certain labels are inappropriate, such as tritium, which could 
enter the water pool, which turns over slowly, and could then 
35 
be lost by evaporation. S labels are taken up into bile acids, 
14 
and excreted in feces. C labels, on the other hand, are use- 
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ful. With appropriate labelling of tracer, labelled CO^ can be 
14 
acquired and measured. Administration of 1- C-tyrosine or 1- 
14 14 
C-leucine produces a plateau in CC^ specific activity one 
to two hours after the leucine plateau in plasma (23). To deter- 
14 
mine the source of the lag of plateau of oxidized product, NaH CO. 
was administered and the same lag in radioactive CO^ production 
was found, thus it was determined that the lag is due mostly to 
time needed for mixing of CO^ with the excretory pool. Also noted 
was recovery of only 80% of the label. The remainder is either 
fixed or taken up into bone. Thus synthesis and breakdown can 
both be measured if time is allowed for CC^ equilibration. 
An alternative to measuring excreted isotope is to determine 
retained isotope, i.e. that incorporated into protein. External 
counting is feasible if a gamma emitting tracer is used. Work 
has been done with ^Se-selenomethionine, which was given as a 
single quantitated dose. Retained radioactivity was then measured 
at time intervals. Extensive reutilization of this tracer com¬ 
plicates calculations of protein turnover. Also problematic is 
evidence (22) that the tracer is metabolized differently than 
is its naturally occurring analogue, methionine. Apparently it 
is exchanged not with the amino acid pool, but with a selenium 
pool, thus is not useful as a tracer of protein metabolism. 
Certain other amino acids present difficulties in tracer 
studies. Important considerations for suitability of an amino 
acid include kinetics, metabolic interrelationships, and ease 
of measurement. Lysine is an example of an amino acid which has 
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a large free pool and thus plateaus slowly. Tyrosine has a small 
pool, and can be formed irreversibly from phenylalanine, but seems 
to recycle label through carbohydrate or fat, thus delaying the 
CO^ plateau. Glycine can be formed by de novo synthesis, pre¬ 
venting total protein turnover calculations. Leucine reaches a 
plateau in plasma in 6 hours, and its labelled CC^ plateaus in 
8 hours. Formation of CC^ is irreversible. Leucine is particu¬ 
larly suitable as a tracer when labelled in the one position 
since this prevents delay in attaining plateau by preventing re¬ 
cycling of label prior to release of label. 
Once an amino acid has been chosen to serve as a tracer, it 
is necessary to determine its occurrence in body protein in order 
to calculate total protein flux. This is difficult at best, and 
is complicated by the fact that some proteins turn over more 
quickly than do others, and that amino acid composition can be 
quite different between these two groups. These difficulties are 
minimized by comparing measurements made on the same time scale 
with the same tracer. 
Thus, in brief, major considerations in selecting a method 
for studying protein turnover are as follows. The use of radio¬ 
activity facilitates assays, but presents ethical dilemmas in 
children and necessitates limiting administered doses in adults. 
Modern spectrometric techniques have simplified the use of stable 
isotopically enriched natural substrates which have no known 
adverse effects on their recipients. 
Another consideration is which bodily fluids are to be 
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analyzed. Plasma assay allows for shorter studies than does 
urinary assay, so recycling of label is limited. However, flux 
estimates are likely to be low, and the concentration of amino 
acid in total body protein is hard to estimate. 
If plasma assays are desired, choice of amino acid used as 
tracer is important. The tracer should have as quantitatively 
important metabolic options only synthesis to protein and oxi¬ 
dation. The amino acid should be essential, have a small pool 
size, be optically pure (free of D isomer) and, if CO^ production 
13 
is measured, should be labelled in the one-position. Leucine with 1- C 
fits the above description particularly well. 
If it is instead desired to measure excreted end product, 
then typically the tracer must contain nitrogen-15. Difficulties 
arise in that metabolism of any one amino acid is unlikely to 
reflect that of all amino acids. Also, the end product chosen, 
urea (synthesized in liver) or ammonia (synthesized in muscle) 
comes from only a portion of the precursor pool for protein 
synthesis. 
Other considerations, such as routes of administration and 
choice of assay method, must also be dealt with. The available 
spectrometric options for assay will be outlined here, with 
emphasis on the method used in this study. 
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SPECTROMETRIC OPTIONS 
The use of stable isotopes (24) to trace kinetics begins 
with work by Schoenheimer and Rittenberg (25) in the 1940' s who 
showed that body constituents are dynamic using deuterated sub¬ 
strates which produced differences in density and refractive 
index. During the following decades, Meselson and Stahl (26) 
showed that DNA replication is semiconservative using ^N-enriched 
DNA subjected to density-gradient centrifugation. Largely be¬ 
cause of difficulties in obtaining and analyzing for stable 
isotopes, radioactive isotopes subsequently took the lead as 
research tools. Over the last ten years, improved isotope 
separation techniques coupled with advances in electronics have 
allowed for a return to the use of stable isotopes as tracers. 
Techniques used for analysis of stable isotope content 
include: refractive index, density, activation analysis, optical 
emission spectroscopy, IR absorption spectroscopy, NMR spectro¬ 
scopy, and mass spectroscopy. Much interest centers around the 
last two methods. NMR spectroscopy requires a larger sample size 
than other methods but is currently a burgeoning field because 
it represents a particularly attractive non-invasive method for 
analysis of everything from atoms to anatomy. 
Three types of mass spectrometry are currently available: 
dual-inlet, dual-collector isotope ratio mass spectrometry (27) 
is capable of precisely measuring very dilute concentrations of 
/ 
label and is used for labelled CO^ and urea measurements. This 
technique, when used for larger molecules or mixtures of molecules 
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such as those found in a sample of plasma, is a long and tedious 
one since it requires prior separation of the mixture into 
individual components, as in liquid chromatography. Coupling 
(27) a gas chromatograph in line with a mass spectrometer (GCMS) 
allows for single step separation analysis of individual compounds 
for molecular weight. Problems associated with measurements of 
mixtures of amino acids by conventional GCMS include the weakness 
of the molecular ion, and the tendency of amino acids to frag¬ 
ment into low mass ions which fall in the same mass range as 
contaminants, as other expected products, or as GC column 
bleed (27). 
Isotope-ratio-monitoring gas chromatography-mass spectro¬ 
metry (28) (IRM-GCMS) uses a catalytic furnace to combust each 
compound of interest contained in the GC effluent into N^, CO^, 
and H^O for isotope ratio measurement by electron impact in the 
mass spectrometer. Another method, selected ion-monitoring gas 
chromatography-mass spectrometry (27) (SIM-GCMS) maintains an 
intact molecule and measures isotopic abundance in it by chem¬ 
ically ionizing a derivative (in the case of leucine, the N-acetyl, 
n-propyl ester) with methane to produce an intense molecular ion 
plus proton, as well as cluster ions (M+C H )+ and some fragments. 
For mixtures with extremely disparate concentrations of differ¬ 
ent amino acids, the lower intensity cluster ions can be measured. 
An added advantage of the chemical ionization method over the 
electron impact method is the lack of fragmentation of critical 
(labelled carboxyl) groups off of the compound of interest, and 
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the smaller sample size required. A disadvantage of CI-SIM-GCMS 
is the presence of naturally occurring isotopes of each element 
in all molecules which means small differences due to enrichment 
are measured against a relatively large background of isotope. 
Sensitivities for monolabelled compounds are similar by both 
methods. 
The last method, SIM-GMCS, was utilized in this study to 
13 
analyze plasma samples for 1- C- leucine content, whose metab¬ 
olism merits review here. 
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LEUCINE METABOLISM 
There are two potential fates for a molecule of leucine: 
incorporation into protein via standard polypeptide synthetic 
methods, or degradation. It is reported (24) that 20-25% less 
isotopically labelled leucine is available intracellularly for 
these processes than is measured in circulating plasma, and that 
changes in dietary protein intake do not affect the ratio of 
intracellular to extracellular label. 
Leucine degradation proceeds first via transamination with 
^-ketoglutarate by leucine aminotransferase to form ketoisocaproate 
(KIC) and glutamate. KIC is then either oxidized by branched- 
chain keto acid dehydrogenase to form carbon dioxide and iso- 
valeryl CoA or reaminated with glutamate nitrogen to regenerate 
leucine and alpha-ketoglutarate. Labelling of the 1-carbon 
(carboxyl carbon) of leucine results in generation of labelled 
CO^o Studies on (29) perfused animal tissue and homogenate 
systems have shown that in muscle the transaminase is more active 
than the dehydrogenase and that the opposite is true in liver. 
To evaluate the situation in intact humans, Matthews et al 
15 13 
(30) used L-( N, 1- C) leucine and SIM-GCMS to show that in 
post-absorptive humans 10+1 % of KIC formed is oxidized and 
90 + 1 % is reaminated. In the fed state, these percentages are 
21 and 79, respectively. Comparison of data from post-absorp¬ 
tive and fed humans showed that leucine oxidation in humans has 
a rate limiting step KIC decarboxylation. 
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Radio-labelled leucine and KIC were used in dogs (3]) to 
show that there is extensive interconversion between leucine and 
KIC ( 80% leucine -> KIC, 66% KIC —-> leucine) in the 14 
hour post-absorptive state, and that leucine conversion to KIC 
is decreased in the 96 hour fasted state. Also, the rate of 
leucine carbon exit was essentially unchanged over the course 
of the fast, although the rate of KIC carbon exit fell by more 
than one half during the study. Thus, since leucine exit is 
essentially equivalent to incorporation of leucine into protein 
and loss from KIC is essentially equivalent to decarboxylation, 
it is likely that the dog is increasingly conserving the essential 
amino acid leucine during the fast. Short term fasted rabbits 
similarly display (32) a decrease in leucine oxidation, but 
starved rats, conversely, show in vivo (33) and in vitro (32,34) 
increases in BCAA oxidation. 
Infusion of labelled amino acid leads to higher extra¬ 
cellular than intracellular levels of label, since infusion 
occurs into the extracellular space and unlabelled amino acid 
enters the intracellular space via protein breakdown. But, it 
is far more convenient to measure circulating leucine levels than 
it is to determine intracellular levels. Taking advantage of 
the fact that KIC synthesis from leucine must necessarily occur 
13 
in the intracellular environment, labelled 1- C -leucine was 
13 
infused and 1- C - KIC was measured in fed and post-absorptive 
humans maintained on a variety of protein rich and deficient 
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diets. It was found that the ratio of KIC/leucine C enrichment 
was 71-82% in all studies. Thus it is possible to use extra¬ 
cellular leucine measurement over a wide range of experimental 
conditions as a reliable marker of intracellular leucine activities. 
Having obtained an overview of the different ways to study 
protein turnover, and a detailed look at the method employed in 
this study, it is now time to review current knowledge related 
to those aspects of protein turnover to which these methods were 
applied. 
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HORMONAL INFLUENCES ON PROTEIN METABOLISM 
It has been known for quite some time that situations which 
are extremely stressful to the human body lead to hyperglycemia 
which is indistinguishable from diabetes. It has been shown that 
the synergistic interaction of the counterregulatory hormones 
glucagon, epinephrine, and cortisol affects carbohydrate metabolism 
in several ways so as to cause a rise in circulating blood glu¬ 
cose (36). The effects of stress physiological doses of these 
same hormones on protein metabolism in normal humans is of 
interest. Previous studies have been done on the effects of 
individual counterregulatory hormones on protein metabolism and 
will be outlined here. 
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EPINEPHRINE 
Epinephrine has been found to exert an insulin-like effect 
on amino acid metabolism, in contrast to its anti-insulin effects 
on the metabolism of glucose and fat. 
A study (37) on isolated rat hemicorpus using the beta- 
agonist isoproterenol, which does not effect perfusion pressure 
by causing vasoconstriction as does epinephrine, resulted in 
decreased levels of alanine in perfusate, as well as falls in 
the threonine, phenylalanine, glycine, valine, leucine, and iso¬ 
leucine levels. These authors also determined that isoproterenol 
inhibits skeletal muscle protein degradation. 
Animal studies in which epinephrine is infused in pharma¬ 
cologic doses resulted in a decrease in o^-amino nitrogen con¬ 
centration (38). To investigate the effect of sympathomimetic 
amines on the induction of hypoaminoacidemia, rabbits were 
administered various of these drugs subcutaneously. Only epi¬ 
nephrine was found to lower blood amino acid nitrogen in this 
study. 
Isolated muscle studies indicate that epinephrine in physio¬ 
logic dose ranges inhibits muscle proteolysis (39), although 
amino acid uptake is not changed. Epinephrine and isoproterenol 
both markedly decreased rates of alanine and glutamine release 
from isolated rat epitrochlaris, -agonists did not produce nor 
did fi -antagonists inhibit this effect. Of the three ways in 
which epinephrine could induce this effect (reduced amino acid 
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transport out of the cell, inhibition of precursor amino acid 
conversion to alanine and glutamine, or decreased availability 
of precursor amino acids due to decreased muscle protein degra¬ 
dation), the last was felt to be the most likely, since tissue 
amino acid levels do not increase, and addition of precursor 
amino acids to the muscle and epinephrine preparation did not 
affect the inhibitory action of epinephrine. 
Studies to examine the effects of stress levels of epinephrine 
on amino acid profiles (40) in humans were performed on normal and 
insulin dependent diabetic subjects. In normal subjects, epinephrine 
2 
infused at a rate of 12 ywg/m body surface area for five hours 
resulted in a decrease in concentration of each amino acid except 
alanine, with a total amino acid fall of 26%, and a BCAA fall of 
40%, and a 30-40% decline in plasma threonine, serine, oi -amino 
butyrate, glycine, methionine, tyrosine, and phenylalanine. 
Administration of a saline control resulted in at most a 13% 
reduction in glycine, alanine, valine, cystine, leucine and iso¬ 
leucine. Because the hypoaminoacidemic response to the epine¬ 
phrine infusion could be due to an insulin effect (even though 
plasma insulin rose only insignificantly at 30 minutes and then 
returned to baseline (14+lyut U/ml)), a similar study with epinephrine 
and saline control infusion was performed on insulin-requiring 
diabetics receiving a constant insulin infusion. Again, hypo- 
aminoacidemia was induced, except for a rise in alanine. Total 
amino acid decreased by 23%, BCAA decreased by 37%, and saline 
had no significant effect on amino acid levels in plasma of 
insulin infused diabetics. 
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Epinephrine’s ft- adrenergic effects are blocked by the 
competitive inhibitor propranolol. Infusion of propranolol for 
one hour in normal human subjects resulted (40) in no significant 
change in individual amino acid levels. Subsequently, super¬ 
imposed epinephrine infusion produced a rise in epinephrine 
levels two-fold greater than that seen with epinephrine infusion 
alone, and a tendency, though statistically insignificant, for 
plasma insulin levels to fall by 30 minutes, from ll^uU/ml to 
9ytdJ/ml. In this study in which the y^-agonistic effects of 
epinephrine were blocked, amino acid levels did not fall at all. 
In fact, a 10-15% rise was seen in plasma levels of valine, 
leucine, isoleucine, methionine, tyrosine, and phenylalanine. 
Sinces changes in insulin levels could have influenced these 
results, a similar study was done with insulin-infused diabetics. 
Again, propranalol did not effect basal amino acid concentrations, 
did enhance the rise in plasma epinephrine, and blocked the 
hypoaminoacidemic response of epinephrine infusion. 
These studies indicate that stress doses of epinephrine 
induce hypoaminoacidemia by activation of -receptors, which 
is consistent with the rat studies described above in which - 
blockade prevented epinephrine-induced amino acid release from 
skeletal muscle. 
Interesting^ an apparently catabolic action of epinephrine 
demonstrated (41) in studies on rat hemidiaphragm and hearts. 
Hemidiaphgrams from fed rats, when incubated with labelled BCAA 
and epinephrine, tended, though not statistically significantly, 
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to enhance CO^ production. Fasting of the rats for 48 hours prior 
to the study resulted in significant (up to 50%) enhancement 
of CO^ production. In this study, only oxidation of BCAA was 
enhanced by epinephrine. Other amino acids were not affected 
in this way. Rat hearts also showed enhanced oxidation of BCAA 
in the presence of epinephrine if the rats had been previously 
fasted. The authors noted that since epinephrine stimulates 
lipolysis in fasted muscle, and since fatty acids stimulate 
BCAA oxidation (42), enhanced BCAA oxidation by epinephrine may 
in fact be a secondary effect. 
Thus from the above it can be seen that it is not known 
why amino acids fall in humans in response to epinephrine. 
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GLUCAGON 
A variety of studies (48) examined glucagon’s effects on 
circulating amino acids. Surgically or pharmacologically induced 
hypoglucagonemia in dogs or humans produced increases in plasma 
alanine concentration (44,45,46,47). Plasma serine, ornithine, 
and arginine concentrations also rose following pancreatectomy (45). 
Chemically induced glucagon levels mimicing for three hours those 
found in health and disease (48) (333-600pg/ml) produced no change 
in plasma amino acid concentration. However, 48 hour infusion of 
glucagon in therapeutically starved obese subjects produced a 
fall in circulating amino acid levels (49), and uremic patients 
respond to physiologic glucagon infusions with generalized hypo- 
aminoacidemia (48). Supraphysiologic glucagon levels, whether 
induced by glucagon infusion (50) or by a glucagonoma (51), 
produce generalized hypoaminoacidemia. 
Basal glucagon levels have been shown to enhance hepatic 
gluconeogensis (46,52). Glucagon-induced glycogenolysis is not 
markedly effected over the short course at basal levels. Hyper- 
glucagonemia, though, apparently first accelerates glycogenolysis 
and perhaps gluconeogenesis as well (54,55,56), by enhanced 
conversion of glycogenic amino acids. Interestingly, it has 
been shown that (53) the liver responds to changes in glucagon 
levels rather than to absolute levels, and that the response has 
occurred within one hour. 
The other major site where glucagon could exert an influence 
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on amino acid metabolism is in the protein reservoir of muscle 
tissue. Forearm perfusion studies (57) in humans in whom 
glucagon-induced changes in individual amino acids were measured 
showed no meaningful changes in amino acid exchange. Thus 
glucagon’s effects which result in hypoaminoacidemia appear to 
be due to hepatic effects rather than to effects on the muscle 
pool. 
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INSULIN 
Many studies have shown, not surprisingly, that adminis¬ 
tration of insulin causes a decrease in blood amino acid levels (58), 
(59,60). This effect is likely produced through effects on muscle 
tissue as indicated by an early study (61) in which muscle free 
amino acids decreased following insulin administration and by a 
later (62) study in humans in which insulin was shown to inhibit 
forearm amino acid release. 
In vitro work has been done on isolated perfused rat hind- 
quarter (63) and on rat epitrochlaris preparations (64) . In 
these cases, insulin did not effect amino acid release in normal 
rats, but did inhibit alanine and glutamine release in diabetic 
hindquarters. These 2 amino acids, however, are not likely to 
be derived from proteolysis. 
In vitro work on diaphragms, hearts, and hemicorpus has shown 
that insulin affects amino acid levels by four mechanisms: in¬ 
creased amino acid transport into cells, increased protein syn¬ 
thesis, decreased protein degradation, and decreased amino acid 
transport out of the cell (65,66,67,68,69). 
A detailed study (70) on perfused rat hemicorpus examined 
time course effects, hormone dose responses, and possible sites 
of insulin action. Insulin prevented or inhibited amino acid 
release, and promoted uptake of BCAA's. It reduced the absolute 
rate of protein degradation. Interestingly, it was found (70) 
/ 
that physiologic rat plasma insulin levels (25-110^uU/ml) produced 
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a maximal enhancement of protein synthesis, whereas pharmacologic 
doses (500 yxU/ml) were needed to inhibit protein degradation. 
Other indications that insulin exerts its effects on protein 
primarily through effects in muscle come from work in which 
various organs were examined following insulin deficiency induced 
by experimentally induced diabetes (71). Whole animal studies 
(72) are consistent with this observation. Diabetes reduces 
fractional rates of protein synthesis in skeletal muscle by 31% 
and in heart by 56%, but does not effect rates in liver, though 
others have found evidence for changes in liver protein synthesis. 
A recent study (73) examined the role of insulin in regu¬ 
lation of leucine kinetics in dogs. Of particular interest, the 
authors showed that the rate of appearance of leucine was un¬ 
changed by saline control infusion or by acutely induced insulin 
deficiency. Hyperinsulinemia (twice basal levels) produced a 
15% fall in the rate of appearance of leucine after one hour which 
was maintained throughout the study, and a 65% rise in clearance 
by four hours. 
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STEROIDS 
Glucocorticoids, the C-ll oxysteroids secreted by the adrenal 
cortex, in general act to produce a protein catabolic response 
opposite to the anabolic response to insulin (74). To determine 
whether the effects of steroids on nitrogen metabolism were 
exerted at the stage of synthesis and breakdown, or at the stage 
of deamination and urea formation, rats (75) were subjected to 
isolation of their livers from their circulation, thus elimina¬ 
ting urea synthesizing capacities. It was concluded from this 
work that "the protein-catabolic effects of the adrenal cortex 
... are not primarily associated with alterations in the rate 
of urea formation", (75) but rather are exerted on protein 
metabolism itself. 
Steroids were demonstrated to promote muscle protein cata¬ 
bolism, particularly when the gluconeogenetic potential of the 
liver is in demand (76). It was postulated that the correlation 
between amounts of steroid-induced urinary nitrogen excretion and 
steroid-induced liver glycogen accumulation indicates that 
steroids stimulate protein breakdown to make available precursor 
amino acids for gluconeogenesis. Corroborating evidence has 
been gathered (77) and detailed investigations of many aspects 
of this steroid effect have been undertaken, in studies on humans 
and animals, intact and in isolated preparations, to elucidate 
the biochemical, physiologic and pharmacologic mechanisms of 
steroid-induced protein catabolism. Selected studies of particu- 
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lar relevance to the subject investigated in this protocol will 
be reviewed here. 
In an effort to elucidate the mechanism by which steroids 
could exert an inhibitory effect on protein synthesis, their 
effects on peptide chain initiation were studied (78). Previously 
it had been shown (78) that decreased levels of ribosomal RNA, 
due to a decrease in the rate of its synthesis, lowered cellular 
protein synthetic capabilities. Skeletal muscle ribosomes sub¬ 
jected to steroids were less able than normal ribosomes to 
incorporate amino acids into protein. It was known (79) that in 
some cases the rate limiting step in protein synthesis is the 
formation of an initiation complex. Fasting had been shown to 
reduce initiation complex formation (78), and to produce (80) 
elevated glucocorticoid levels, thus it seemed worthwhile to 
search for a link between these two results in the form of a 
steroid regulatory effect on initiation complex formation. 
Rats which received (78) five days of cortisone acetate 
subcutaneously (10 mg/100 g initial body weight) showed a re¬ 
stricted rate of peptide chain initiation in psoas muscle, but 
not in heart muscle. Post-ribosomal supernatants of psoas muscle 
showed 25-35% lower binding activity of Met-tRNA^met (which is 
involved in initiation complex formation) after cortisone treat¬ 
ment for five days and after shorter-term treatment with dexa- 
methasone (l^ttg/g bdy wt), eIF-2m (78,81), the initiation factor, 
exhibited impaired activity after cortisone, but not after dexa- 
methasone, treatment. 
■ 
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Administration of dexamethasone (8mg) daily for 5 days to 
rats produced a negative nitrogen balance, largely due to an 
increase in urea excretion (82). Three possible mechanisms were 
considered to account for this effect: (1) Enhanced activity of 
the enzymes of urea synthesis, (2) increased pyruvate synthesis 
leading to elevated alanine levels and thus to increased urea 
formation, or (3) increased muscle proteolysis, providing the 
liver with more urea precursors. The first hypothesis was thought 
to be unlikely since the urea cycle has such a large basal 
capacity; the second was dismissed since it has been shown (83) 
that muscle derived alanine is not synthesized from circulating 
pyruvate. The authors felt that the last mechanism was most 
consistent with their data, which showed a statistically signi¬ 
ficant increase in plasma levels of alanine and glutamine es¬ 
pecially, as well as of arginine, methionine, and phenylalanine. 
Dexamethasone did not significantly effect plasma concentrations 
of other amino acids, but did result in a significant increase 
in levels of insulin (10 juU/ml to 24U/ml, p < .025) and of 
glucagon (111 pg/ml to 150 pg/ml, p < .05). These hormonal rises 
were not significantly correlated with increases in urea nitro¬ 
gen excretion. The only variables tested which proved to be 
significantly correlated with elevated urinary urea nitrogen 
were alanine and glutamine which are potential donors of nitro¬ 
gen in urea forming reactions. 
Cortisone acetate (lOmg/lOOg initial body weight/day) in 
a dose shown to simulate plasma glucocorticoid levels in severely 
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stressed rats and to accelerate muscle protein breakdown (84) 
was administered to rats for 5 days (85), who experienced total 
body weight loss as well as loss of weight in most muscle groups 
studies. Blood and muscle amino acid levels declined or remained 
unchanged, except for isoleucine and phenylalanine which rose in 
blood. 
In perfused rat hemicorpus, (85) cortisone treatment produced 
increased release of almost all amino acids. Five days of corti¬ 
sone perfusion reduced muscle protein synthesis by 40% of control, 
although efficiency and capacity for protein synthesis were not 
changed. Protein degradation was not effected by steroid treat¬ 
ment . 
Further studies (86) in which rats were subjected to high 
dose triamcinolone and were then studied for steroid receptor 
populations of specific muscles led to the suggestion that muscular 
atrophy in these cases is caused by increased rates of protein 
degradation, or that cytosolic receptor population is not directly 
related to tissue response to glucocorticoids. 
To examine the relative contributions of protein synthesis 
and protein degradation to steroid induced effects on protein 
turnover, rates (87) were given triamcinolone acetate IP (95mg/kg 
body wt). Breakdown rate was calculated by subtracting fractional 
rate of net change from fractional rate of synthesis. Fractional 
synthesis was 84% of control, and fractional breakdown rate was 
126% of control, after two days of treatment. The authors point 
out that since the glucocorticoids induced hyperinsulinemia (88), 
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it is difficult to sort out causes for catabolic and anabolic 
processes in such situations in which insulin levels are permit¬ 
ted to rise. 
The effects of IM injections of corticosterone (1.5 mg/kg) 
were compared with those of experimentally induced transient 
hypovolemia in rabbits whose muscles were then excised at 24 and 
14 
72 hours post steroid injection and were incubated with 1- C- 
leucine (89). Measurement of leucine oxidation and leucine 
incorporation into trichloracetic-acid-precipitable protein was 
thus possible. Leucine oxidation to carbon dioxide was signi¬ 
ficantly increased compared with control animals, and the effect 
was more sustained over time, though of less magnitude, in post¬ 
shock rabbits than in steroid recipients. The authors attribute 
their results to increased protein breakdown enhanced by oxidative 
removal of the rate determining essential amino acid leucine from 
the plasma pool. 
In a study employing radioactive leucine as tracer, rats who 
received daily injections of cortisone acetate (10 mg/day) showed 
marked atrophy of skeletal muscle. The hormone decreased the 
amount of labelled protein per muscle, but did not alter the 
specific activity of the protein (90) . Thus cortisone both in¬ 
creased protein degradation and decreased protein synthesis. 
Other studies (91) examining the synthesis and breakdown 
rates of proteins were conducted. Rats received injections of 
cortisone acetate (100 mg/kg) for 1 to 3 days. In this case 
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cortisone inhibited both protein synthesis and protein breakdown. 
Thus it was concluded that glucocorticoid-induced muscle wasting 
is largely due to interference with protein synthesis. The authors 
argue that the previous study, which did demonstrate increased 
muscle protein breakdown, was subject to error due to reutiliza¬ 
tion of the labelled amino acid derived from protein breakdown. 
From the above presentation it is seen that it is quite 
difficult to ascertain from the literature precisely what the 
effects of steroids are on protein metabolism. This is due to 
the difficulty in sorting out the contributions of duration of 
studies, subjects of studies, dose or choice of steroid, method 
of measurement, etc. to the results, which are therefore disparate. 
Work (92) has been done in humans as well to examine the 
effect of glucocorticoids on protein metabolism. 3 days of 
dexamethasone (2 mg/d) resulted in a 40% increase in plasma 
alanine concentration. 14 other amino acids were unchanged. 
Patients with Cushing’s syndrome also had a 40% elevation in 
alanine and had otherwise normal amino acid levels. Thus the 
steroids induced hyperalaninemia, which may have contributed 
to the parallel rise in glucagon. 
There appear (93) to be time related differences in amino 
acid response. Initially a transient elevation is seen (94) 
followed by a decline. Perhaps this is due to the changes in 
insulin levels seen with steroid infusions of different dura¬ 
tions . 
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A study of the acute changes in amino acid levels in response 
to steroids (94) was done in our laboratory, where it was shown 
that administration of cortisol for 5 hours results in signifi¬ 
cant elevations of the BCAAs and of phenylalanine. 
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CLINICAL APPLICATIONS 
Hormonal elevations and protein metabolic changes are well 
known sequelae of a variety of medical and surgical stress 
situations. Because our study was conducted to simulate the 
hormonal conditions of stress, it is useful to consider the evi¬ 
dence that led to the recognition that stressful situations 
reliably produce endocrine responses in non-compromised hosts. 
Glucagon levels have been shown to rise in bacterial infec¬ 
tions (95). Whereas a normal control mean fasting concentration 
of 75+4 pg/ml was found, five mildly infected patients had an 
average of 69 + 16 pg/ml, 11 moderately infected ones had 185 + 31, 
and six severely infected ones had 409 + 129 pg/ml. Insulin 
levels in the sickest cases were not significantly different from 
the average of 10 + 2 yuU/ml, despite infusion of D5W in some 
patients. 
Patients with myocardial infarction (96) similarly demon¬ 
strated a significant rise in glucagon levels compared with 
normals. Those without cardiac disease had an average level of 
82+6 pg/ml, acute coronary insufficiency produced levels of 
80+5, and acute myocardial infarction led to 125 + 15. Cardio¬ 
genic shock in the absence of exogenously administered catechols 
gave an average level of 213. Values did not fall significantly 
in the first 48 hours of hospitalization. Insulin did rise 
(26 + 4 ^u.U/ml compared with 9+1) in acute myocardial infarction 
compared to normals. 
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Epinephrine and norepinephrine concentrations (96) were 
found to be significantly higher in patients with acute myo¬ 
cardial infarcts than in normals. The mean plasma catecholamine 
concentration correlated with degree of illness. The changes 
in catecholamine levels did not correlate with each other, 
however. In a study of abdominal surgery patients, the change 
in norepinephrine did correlate with the change in epinephrine 
concentration (97). Epinephrine levels rose from 70 + 10 pg/ml 
to an intraoperative high of 330, and norepinephrine rose from 
180 + 20 to 560 pg/ml. 
Catecholamine and steroid levels were monitored (98) in 
surgical patients in another study. A rise in 17-hydroxy 
steroid was seen, which persisted for about 38 hours. In patients 
in shock or with other complications, levels of steroid were 
very high. Post-operative complications also prolonged the ele¬ 
vation. In these patients, epinephrine levels were more closely 
correlated with the degree of stress than were norepinephrine 
levels. 
In another study examining surgical patients, general cor¬ 
relation was found between severity of surgery and plasma cortisol 
rise, although individual patient response varied quite a bit (99). 
After minor procedures, 20 patients displayed a maximum cortisol 
level of 28 + 2/dg/100ml, which was an increment of 18 + 2.7. 20 
major operations produced maximum levels of 47 + 2.9, an increment 
over baseline of 36+2.6. Steroid elevations were sustained 
above the upper limit of normal (26 at 9 A.M.) for up to 72 hours 
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in severe stress. Steroid elevations were also demonstrated in 
myocardial infarct patients with extensive infarct or in those 
who had been resuscitated following cardiac arrest. These 
patients had 11-OHCS levels of greater than 50 jug/ 100ml compared 
with myocardial infarct patients with a minor degree of tissue 
destruction who had levels less than 30 (100). 
The effects of various stressors on protein metabolism in 
intact mammals has been studied by many. Cuthbertson was the 
first to note that injury to the limbs produced a protein cata¬ 
bolic response (101). In an early attempt (102) to determine 
whether slowed tissue repair or increased tissue breakdown is 
responsible for the negative nitrogen balance seen in bed-ridden 
patients, measurements were made of urinary nitrogen-15 excretion 
after administration of N^-labelled glycine. The results seemed 
to indicate that reduced synthesis occurred, and breakdown rate 
was unchanged. However, a study employing a pulse injection of 
L-^N-alanine in septic patients yielded results suggestive of 
"a rise in the rates of clearance of the increased flux of amino 
acids, both by utilization, i.e. synthesis, and by excretion as 
urea" (103). Evidence confirming that whole body protein synthesis 
and breakdown could be increased at the same time was obtained 
from children recovering from burns (104). 
The nitrogen wasting following surgery was generally thought 
to be due to an increased rate of protein breakdown (105). To 
determine whether a decrease in the rate of protein synthesis 
14 
could be more important, C-leucine in a continuous infusion was 
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administered to patients post-operative from abdominal surgery (105). 
In fact, the authors found a consistent decrease in protein syn¬ 
thesis rate. Confirmatory evidence is presented in a study of 
patients undergoing elective orthopedic surgery, in whom, although 
nitrogen wasting was only moderate, almost all of it was due to 
a decreased rate of synthesis (106). 
At variance with the above results is a study in which whole 
body protein breakdown rate was found to increase following acci¬ 
dental trauma. Measurements of urinary 3-methyl-histidine, a 
muscle protein marker, indicated that the skeletal muscle contri¬ 
bution to protein breakdown was almost twice that seen in normal 
controls (107). 
A reasonable explanation for the variability of response 
of protein metabolic functions to different sorts of stress is 
that severity of stress is an important determinant of outcome 
(108). Thus perhaps moderate stress decreases protein synthesis 
and severe stress causes a relative increase in protein synthesis 
as well as an increase in breakdown. A study supporting this 
view showed that in severe skeletal trauma, protein synthesis 
increased by 37% and breakdown increased by 79%, 
The steroid infusion protocol was also designed to simulate 
clinically important situations. Excess of circulating gluco¬ 
corticoid can be due either to iatrogenic causes (administration 
of any of a variety of steroids for any of a myriad of reasons, 
real or imagined, in acute and chronic doses) or to naturally 
occurring cortisol excess, again from any of a variety of sources 
producing Cushing's syndrome. Clinically this steroid excess 

38 
produces a variety of symptoms, of which a major complaint 
related to protein metabolism is muscle weakness. 
29 of 50 (58%)of patients (109,110) in one study of Cushing's 
syndrome mentioned muscle weakness as a problem. Typically this 
is proximal, involving the lower extremities, and thus presenting 
difficulty in climbing stairs and arising from chairs. Drug 
induced steroid myopathy is occasionally sudden in onset, but 
more typically occurs gradually, over weeks to months. Again 
primarily proximal muscles are effected. Myalgias are associated 
with the weakness. Since steroids are almost ubiquitous in 
clinical medicine, further understanding of mechanisms underlying 
their effects are warranted. 
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EXPERIMENTAL PURPOSE 
As outlined previously, studies of steroid effects on 
protein metabolism are complicated by differing results which 
can be partly attributed to differences in administered doses, 
length of dose administrations, concomitant changes in concen¬ 
tration of other hormones, and perhaps other unrecognized factors. 
In studies on normal humans (111) Dr. Sherwin and co-workers 
have shown that BCAA levels rose by 40% in response to the same 
steroid dose as employed in the study reported in this work. 
Administration of labelled leucine should provide a means of 
estimating the contribution of rates of protein synthesis and 
breakdown to the hyperaminoacidemia induced by the steroids. 
The cortisol protocol also served as an important comparison 
for the triple hormone infusion protocol. An interesting question 
was raised by work done previously in this laboratory (112). 
Each of the three hormones was infused in stress doses separately 
into dogs, and then in combination. A more than additive effect 
of these three hormones was observed, thus producing marked 
hyperglycemia such as that seen in conditions of severe stress, 
in which hormone elevations are well known to occur as outlined 
earlier. A subsequent study (113) in normal humans employing 
a triple hormone infusion suggested that the synergistic inter¬ 
action of these hormones could well account for the common clinical 
phenomenon of stress hyperglycemia. 
The question of whether these hormones were acting in con- 
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cert, synergistically or in some other fashion on other metabolic 
processes (such as amino acid metabolism) thus merited study. 
Again using labelled leucine as a tracer, it is possible to 
investigate the mechanisms underlying the effects of this in¬ 
fusion on protein metabolism in normal humans over the short 
term. 
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Subjects 
Five healthy normal volunteers, male, aged 18 to 34 years, 
were studied on two occasions each. Clinical data are given in 
Table 1. All subjects were within 15% of ideal body weight 
based on 1959 Metropolitan Life Insurance Company Tables. They 
consumed self-selectedweight maintaining diets and were taking no 
drugs. None of the subjects had intercurrent illness at the 
times of study. All had normal fasting plasma glucose concentra¬ 
tions, {less than 100 mg/dl), and denied a family history of 
diabetes mellitus. Each subject was informed of the nature, 
purpose, and possible risks of the studies as.approved by the 
Human Investigation Committee of Yale University School of 
Medicine, before obtaining the subject's written voluntary consent 
to participate. 
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2 
Subject Age Sex Height (cm) Weight (kq) BSA (m ) 
J 25 M 68 76.4 1 . 90 
H 23 M 72 69 1.897 
F 18 M 67 60. 7 1.70 
M 18 M 74.5 101.8 2.29 
C 34 M 69.5 77.3 1 . 94 
The patients described above each received naturally 
labelled leucine enriched in carbon-13 to permit kinetic 
calculations based on tracer abundance. Data from two 
additional patients who received unlabelled leucine is 
included in all results except those requiring calculations 
based on tracer abundance. 
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Experimental Protocol 
All subjects were studied in the post-absorptive state after 
a 10 to 14 hour overnight fast. A 19-guage polyethylene catheter 
was inserted into an antecubital vein far blood sampling and 
into the contralateral vein for administration of tracer and of 
hormones. The blood drawing line was kept open with a slow 
infusion of normal (0.9%) saline. Two experimental protocols 
were employed in each subject. The order of study was randomized. 
In each study, three hours before cortisol infusion, at -180 
13 
minutes, a primed-continuous infusion of 1- C-leucine (KOR 
Isotopes, Cambridge, Mass.) was initiated with the priming 
intravenous dose of 0.26 mg/kg injected rapidly, immediately 
followed by a continuous infusion (harvard Apparatus Co., Millis, 
Mass.) of 0.31 mg/kg/hr for the remainder of the study. A priming 
13 
dose of NaH CO^ (KOR Isotopes, Cambridge, Mass.) of O.llmg/kg 
was also given rapidly at -180 minutes. Before administering 
hormones, a three hour equilibration period was allowed for leucine 
13 
tracer to achieve steady state. NaHCO^ equilibrates the CO2 pool. 
At time 0, cortisol hemisuccinate (solucortef, Upjohn, Kalamazoo, 
Michigan) was prepared in sterile 0.9% saline, and administered 
2 
as a primed continuous infusion of 10 mg/m body surface area for 
2 
two hours, followed by a continuous infusion of 5 mg/m /hr. Body 
surface area was calculated from an algorithm employing the 
subject’s weight and height on an Olivetti P6060 computer. 
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In one of the two experimental protocols, two hours after 
starting the cortisol infusion, continuous infusions of epinephrine 
2 
(1.2 jx g/m BSA/min, Adrenalin chloride, Parke, Davis and Co., 
Detroit, Michigan) and of glucagon (3 ng/kg/min, Eli Lilly and Co., 
Indianapolis, Indiana) were instituted for the remaining four 
hours of the study. These infusates were freshly prepared in sterile 
0.9% NaCl. Ascorbic acid (1 mg/ml of infusate) was added to the 
epinephrine solution to protect against oxidation. Sterile human 
albumin (300 mg/dl) was added to the glucagon infusate to prevent 
adsorption of glucagon to plastic tubing during delivery. 
Sampling Procedures 
Blood for glucose measurement was drawn at times t = -180, 
-45, -30, -15, 0, 30, 60, 120, 180, 240, 315, 330, 345, 360. 
Samples were immediately centrifuged and the plasma was 
separated for glucose assay. 
Samples for plasma immunoreactive insulin determination 
were collected in chilled heparinized tubes at t = -30, 0, 120, 
180, 315, 360 minutes. 
Three milliliters of blood for immunoreactive glucagon 
determination was added to each chilled tube containing 10.5 mg 
EDTA and o.3 ml trasylol. Samples were collected at t = -30, 0, 
120, 240, 315, 360 minutes. 
Samples for cortisol determination were collected in chilled 
EDTA-containing tubes at t = 0, 120, 240, 315, 360. 
Samples for catecholamine determination were collected in 
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chilled tubes containing reduced glutathione at times t = 0, 
120, 315, 360. 
Blood for measurement of plasma amino acids was obtained in 
heparinized tubes at the same time points at which glucose was 
assayed. Expired air was collected in a weather balloon by 
having the subject breathe normally into a Rudolph valve and 
mouthpiece. Samples of air for assay were transferred via needle 
to vacuum collection tubes. 
In all cases except glucose determination blood was centri¬ 
fuged at 2500 rpm under refrigerated conditions (4°C) to separate 
plasma, which was then stored at -20°C. Samples for amino acid 
determination were deproteinized with 10% sulfosalicylic acid 
following initial centrifugation and then respun at 8000 rpm 
prior to storage at -20°C. 
At three intervals during the study, C>2consumption and C02 
production were measured (-120 to -60 minutes, 60 to 120 minutes, 
and 240 to 300 minutes). The subject's head was placed in a 
sealed box with one-way air inflow and air uptake tubes attached. 
The subject was instructed to relax and remain as still as possible, 
but not to sleep. The outflow tube was interrupted by C02 and C>2 
sensors which fed into analyzers (Applied Electrochemistry Inc., 
Sunnyvale, California). An Omniscribe recorder (Houston Instruments) 
recorded the %C02 and %02 of the subject's expired air on a contin¬ 
uous plot. At specified time intervals, the volume of gas passed 
through the chambers was recorded from a Singer recorder (American 
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Meter Division), Temperature and barometric pressure were obtained 
from the National Weather Service, 
CHEMICAL ANALYSIS 
The plasma glucose concentration was determined by the 
glucose oxidase method (117) on a Beckman Glucose Analyzer 
(Beckman Instruments, Fullerton, California). 
The immunoreactive insulin concentration was determined by 
radioimmunoassay with talc to separate bound from free insulin 
(118) . 
Plasma immunoreactive glucagon was measured by radioimmunoassay 
using the Unger 30K antibody (Diabetes Research Fund, Dallas, 
Texas) {119). 
Plasma cortisol was assayed by a fluorometric method (120). 
Plasma catecholamines were measured using a radioenzymatic 
technique (121), 
Plasma amino acids were assayed by automatic ion-exchange 
chromatography (Dionex Corporation, Sunnyvale, California) (122). 
SPECTROMETRIC ANALYSIS 
Leucine 
13 
Assays for plasma C-leucine were performed according to the 
method of Matthews et al (123). Th& free amino acids were 
isolated from plasma by an ion exchange column (124, 125). The 
N-acetyl, n-propyl (NAP) amino acid ester derivative was prepared 
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and stored at -20°C (124). Gas chromatographic separation of the 
NAP esters was performed over a mixed phase column. Leucine was 
separated at 115°C from a 1 jul injection of sample. Ester residue 
was burned off at 240°C intermittently to improve isolation. 
Methane gas was used as a carrier for the CI-GCMS. 
Selected ion monitoring measures the (M + H + 1) + and the 
(M + H)+ ions, thus allowing calculation of the background-corr- 
4 4 
ected isotope ratio of (M + H + 1) /(M + H) , defined as R_,, for 
the jth sample taken during the study. To eliminate the contribu¬ 
tion of natural abundance isotope to the value, A R ^ is calculated 
AR. = (1/b) (R. - R ) 
1 jo 
where b is the slope of a calibration curve determined daily to 
correct for long term machine variation, and R is the ratio for 
o 
the preinfusion sample, representing natural abundance of isotope. 
Atom percent excess enrichment (APE), E ., is calculated; 
E_. = ARj/( 1 + Rj) x 100. 
Carbon dioxide 
13 
Tubes for analysis of CO2 are attached to the sample inlet 
of a dual-viscous-leak-inlet dual-collector isotope ratio mass 
13 
spectrometer (Nuclide Corp., State College, Pennsylvania). C 
13 
enrichment, as APE C, is measured against a sample of C02 of 
known enrichment, and APE ^^C is then calculated by subtracting 
13 
APE C content of the unenriched preinfusion CO^ sample. 
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CALCULATIONS 
Leucine turnover, or flux, Q, is calculated from isotopic 
enrichments 
Q = i (E./E - 1) 
i P 
where i = leucine infusion rate in ^^umol/kg/hr, e_^ = enrichment of 
labelled leucine infused expressed as APE, E = leucine enrichment 
P 
in plasma at isotopic plateau in APE. 
Leucine oxidation, or C, is calculated as follows: 
where 
C = F,_ (1/E - 1/E.) x 100 
p l 
co2 
where F, 
CO 
F =(F E /W)(60 x 44.6)/(100 x 0.81) 
C02 U2 LU2 
2 is C02 production rate in ml/min, E is enrichment of 
C02at steady state in APE, W is the subject's weight in kilograms, 
the first three constants are for conversion, and the last accounts 
for that carbon dioxide released from leucine but not expired in 
air. F is the product of corrected flow rate in liters/min 
C°2 
and the difference between expired C02 and room air CC>2. The 
flow rate is obtained from the change in volume per unit time, and 
is then corrected to standard temperature and pressure. 
Leucine incorporation into protein, S, is calculated from the 
standard model (125,126) 
S = Q - C. 
Leucine release from protein, due to protein breakdown, is 
B = Q - I. 
Since leucine exogenous intake in the post-absorptive state is zero, 
in this case B = Q. MCR, metabolic clearance rate, at plateau is 
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MCR - Q (leucine concentration at plateau). 
To determine values for whole-body protein turnover, synthesis, 
and breakdown, the corresponding leucine parameters are multiplied 
by (24 hrs/day)/(590 yumol leucine/gram protein). The latter is 
an average value for leucine content of protein in human flesh and 
other mammal muscles (127, 128). 
The above calculations are applied only to steady state 
situations. To determine the rate of appearance of leucine, R , 
and the rate of disappearance of leucine, R , during the period 
prior to attainment of the final plateau, a single pool non-steady 
state model is used (129). 
1 “ (p! + V (Ea2 ' Eal> 
(Ea2 + Ea^ 
2 
where i = tracer infusion rate ( mol/kg/min), P = pool size at 
time t, Ea = APE at time t 100. 
R,= R (P2 * Pl> 
d a - 
(t2 - tx> 
and metabolic clearance rate, MCR is: 
R, 
MCR = 
A1 + A2 
where A is the leucine concentration in plasma at time t. 
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Oxygen consumption is equal to carbon dioxide production 
divided by the respiratory quotient, RQ. The latter is 
derived from comparison of the subject's expired carbon 
dioxide and oxygen with values for these gases in room air. 
STATISTICAL METHODS 
All values represent the mean of duplicate determinations 
of each sample. Data in the text, tables, and figures are given 
as the mean + the standard error (S.E.). Statistical analyses 
were performed using the Student's t-test. Paired t-tests were 
used where applicable (129)„ 
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RESULTS 
CORTISOL PROTOCOL 
Cortisol levels 
The mean preinfusion cortisol level averaged 11 + 1 /u. g/dl. 
After the two hour priming infusion of exogenous cortisol, plasma 
cortisol levels were elevated significantly, to 39 + 4 jxg/dl 
(p< .001 vs. basal value) and remained so throughout the remainder 
of the study. During the rest of the cortisol infusion plasma 
cortisol levels ranged from 43+6 (p< .005) at four hours to 34 + 
3 (p < .001) at six hours. (See figure 1). 
Effect of Cortisol Infusion on Glucose Levels 
Cortisol induced a statistically significant increase in 
circulating plasma glucose levels beyond four hours. Mean pre¬ 
infusion glucose levels were 89+3 mg/dl. Initially, plasma 
glucose remained stable for two to three hours. Thereafter, 
glucose levels gradually increased, becoming statistically signif¬ 
icant at four hours (99 + 4, p < .01) and reaching 101 + 5 (p <.01) 
at six hours. (See figure 2). 
Effect of Cortisol Infusion on Plasma Insulin and Counterregulatory 
Hormones 
Insulin levels remained remarkably stable during the course 
of the study, despite the rise in plasma glucose. The baseline 
pre-infusion level was 12 + 1 ,u.U/ml, and the range throughout 
the study only varied between 11 and 13 xtU/ml. (Figure 2). 
There were no significant changes incplasma glucagon levels 
during the six hour cortisol infusion when compared with the pre¬ 
infusion mean level of 187 + 49 pg/ml. Nevertheless, glucagon 
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levels tended to rise slightly throughout the study (to 207 + 54 
pg/ml at six hours), with the largest change occurring in the 
last 45 minutes of study. (See figure 1)» One patient displayed 
particularly high glucagon levels throughout the study, thus 
accounting for the large standard error for each point. His 
elevated levels were most likely non-biologically active glucagon, 
which is measured by the assay used in a manner indistinguishable 
from biologically active glucagon. 
Plasma epinephrine concentration also was not statistically 
altered by the cortisol infusion, despite a high baseline value 
of 178 pg/ml in one subject, most likely due to anxiety-induced 
epinephrine release. Mean pre-infusion epinephrine levels were 48 
+ 22 pg/ml, and values during the six hour infusion ranged between 
37+4 pg/ml and 27+6 pg/ml. (See figure 1). Similarly, 
plasma norepinephrine concentration (300 + 83 pg/ml, basal), was 
not significantly affected by the cortisol infusion. 
Effect of Cortisol Infusion on Amino Acid Levels 
Table 2 demonstrates the plasma levels of acidic and neutral 
amino acids during the cortisol infusion. Cortisol caused a 
specific elevation in the branched chain amino acids, leucine, 
isoleucine, and valine, but had no significant effect on all 
other amino acids. Plasma leucine, isoleucine, valine and total 
branched chain amino acids rose by 41%, 30%, 18% and 23 % respec- 
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tively» (See figure 3). In the five subjects receiving the 
stable isotope infusion, plasma leucine rose from 116 + 7M to 
165 + 14at six hours, (See figure 3). 
Effect of Cortisol on Leucine Enrichment 
There was no significant change in enrichment of leucine 
between the pre-infusion mean and the final plateau values. 
There was a tendency toward higher values in the intervening period, 
though not a significant one. The pre-infusion mean level was 
1.82 + 0.053 APE and plateau values were in the range 1.90 to 
1.86 APE. (See figure 3). 
Effect of Cortisol Infusion on CO^ Production and Enrichment and 
on C>2 Consumption 
Mean CO^ production as calculated from volume and composition 
of expired air did not change significantly over the course of the 
study. Pre-iri fusion levels were 194 + 18 ml/min, and towards the 
end of the study (four to five hrs) levels were 204 + 19 ml/min. 
CO2 enrichment also showed no significant change during the study. 
Oxygen consumption rose somewhat during the study, from a 
pre-infusion level of 251 + 23 ml/min to 286 + 28 ml/min from 
four to five hours. 
Calculations 
Steady state calculations employing the equations described 
earlier were performed for four pre-infusion baseline values and 
for four plateau values collected at the end of the study. 
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Results show that A, the rate of leucine flux, C, the rate of leu¬ 
cine oxidation, and S, the rate of leucine incorporation into 
protein, were all statistically similar during the baseline 
period and the final plateau period. Metabolic clearance rate 
(MCR) was demonstrated to have changed quite significantly, from 
a baseline of 1.01 + 0.06 to a plateau of 0.71 * 0.04, a fall of 
30%„ (See table 3). Because no difference had been seen in 
Q, S or C, it was decided to apply non-steady state kinetic 
equations to the non-plateau time periods, to examine the rate 
of appearance, R , and the rate of disappearance, R , of leucine, 
3. Q 
and thus to gain insight into the causes for the decrease of MCR 
during the study. 
Assumptions regarding pool size can have a significant 
effect on the results obtained from calculations of R and of R,, 
a d 
so all calculations were done twice, once using a pool fraction of 
0,15 and once using a pool fraction of 0.45. In both cases, there 
is a tendency for R^ to fall, and for R^ to fall somewhat more 
during the study, though these trends are not significant. Results 
are graphed in figure 4, 
Figure 4 also shows that using a larger pool fraction, in this 
case 0.6, tends to increase the difference between R and R when 
they are calculated from the mean values for each time period and 
compared with similar calculations using a pool fraction of 0.15. 
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CORTISOL/EPINEPHRINE/GLUCAGON PROTOCOL 
Cortisol Levels 
The mean pre-infusion cortisol level averaged 10+1 ^g/dl. 
After the two hour priming cortisol infusion, plasma cortisol 
levels rose significantly, to 46 + 6 ^g/dl at two hours (p < .001) 
and then fell only slightly during the remainder of the study, to 
37 + 4 u g/dl at six hours, p< .001. (See figure 1). Plasma 
cortisol levels during the combined hormone infusion were not 
significantly different from values observed during infusion of 
cortisol alone. 
Glucagon Levels 
Mean pre-infusion glucagon levels were 173 + 50 pg/ml, and 
did not rise significantly until after the glucagon infusion was 
begun two hours after the onset of the cortisol infusion. At 
four hours (two hours after beginning the glucagon infusion), mean 
levels averaged 442 + 79 pg/ml, which was significantly different 
from baseline (pC.OOl). Thereafter, plasma glucagon remained 
elevated in this range until the end of the study. (See figure 1). 
Catecholamine Levels 
Mean pre-infusion epinephrine was 45 + 30 pg/ml, and remained 
stable after cortisol was infused for two hours. When epinephrine 
was added, plasma epinephrine rose to 550 + 111 pg/ml by the 
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completion of the study (p< .02 vs basal period). A sample 
obtained 45 minutes earlier was in this range, suggesting that 
plateau had been reached. (See figure 1). Previous studies 
have shown that epinephrine levels reach a stable plateau within 
one hour using an identical protocol. 
In contrast, norepinephrine levels did not change significantly 
during the course of the study. 
Effect of Triple Hormone Infusion on Glucose Levels 
The combined hormone infusion induced a significant increase 
in plasma glucose concentrations. Mean pre-infusion levels were 
91+2 mg/dl, and 94+3 mg/dl after the two hour cortisol infu¬ 
sion. When all three hormones were infused together, plasma 
glucose rose to 159 + 7 mg/dl within one hour (p < .001). By the 
end of the infusions plasma glucose stabilized at 180-190 mg/dl. 
Plasma glucose levels were significantly higher during the combined 
hormone infusion as compared with the cortisol infusion alone (p<.001). 
(See figure 2.) 
Effect of Hormones on Insulin Levels 
Mean pre-infusion insulin levels were 13+1 uU/ml and were 
unchanged during the two hour period that cortisol was infused 
alone. After glucagon and epinephrine were added, plasma insulin 
rose to 21 + 3 (p .005) within one hour. Thereafter, insulin 
levels continued to rise, reaching a maximum of 28+4 aU/ml at 
the end of the infusions. (See figure 2). In the final four 
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hours of the study plasma insulin levels were two-fold higher 
than those during cortisol infusion alone (p < .005). 
Effect of Hormonal Infusion on CO^ Production and 0^ Consumption 
Mean CC>2 production changed significantly from 200 + 23 ml/min 
at pre-infusion to 249 + 20 during hour four to five (p< .005). 
Oxygen consumption increased significantly, from 250 + 26 ml/min 
to 315 + 28 ml/min (p < .005) . Triple hormone infusion did induce 
a significant (p <.01) increase in production when compared 
with cortisol infusion alone; the increase in 0^ consumption 
induced by the triple hormones was not significant when compared 
to cortisol alone. 
Effect of Triple Hormone Infusion on Amino Acid Levels 
Table h demonstrates the plasma levels of acidic and neutral 
amino acids during the triple hormone infusion. The hormones 
caused a significant fall in total branched chain amino acids (42%, 
p<„001), leucine (45%, p<.001), isoleucine ( 50%, p<.005), 
valine (40%, p < .001), as well as in the following amino acids: 
threonine (47%, p<.001), serine (48%, p< .001), glutamine (20%, 
p <.05), glycine ( 42%, p<.005), tyrosine (50%, p<.001) and phenyl¬ 
alanine (29%, p<.05). During the last hour of the study, a signi¬ 
ficant rise was noted in plasma alanine levels (20%, p < .05). 
No change was noted in cystine or taurine levels. 
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Effect of Triple Hormone Infusion on Enrichments 
Data for the two patients whose enrichments have been 
calculated are displayed graphically in figure 5. They 
display a slight rise in leucine enrichment in response to 
the triple hormones, and a slight fall in carbon dioxide enrich¬ 
ment . 
Calculations 
Results for these two patients are displayed in table 5. A 
slight fall in Q, C, and S, is seen over the course of the study, 
and a large rise in MCR is found. Data from the remaining three 
patients are needed to allow calculation of any significant trends 
which may be present. 
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VARIABLE 
Q 
c 
s 
MCR 
Table 3. 
PRE-INFUSION 
115.6 + 3.4 
18.2 + 2.7 
97.4 + 3.9 
1.01 + 0.06 
END-OF-INFUSION 
113.0 + 3.5 
17.3 + 1.4 
95.7 + 3.9 
0.71 + 0.04a 
Mean values from separate calculations of values 
for five subjects for Q, leucine flux, C, leucine 
oxidation, S* leucine synthesis to protein, and 
MCR, leucine metabolic clearance rate. Data are 
presented as x + SEM. End-of-infusion values are 
not significantly different from pre-infusion values 
except as noted. 
indicates p ,005 as compared with the pre-infusion 
value. 
CORTISOL PROTOCOL 
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VARIABLE (SUBJECT) PRE-INFUSION END-OF-INFUSION 
Q M 104.0 93.1 
C 105.1 92.5 
C M 21.5 12.2 
C 17.0 19.2 
s M 82.5 80.9 
C 88.0 73.7 
MCR M 0.76 1.29 
C 0.71 0.98 
Table 5, Values for calculations for two subjects (M and < 
Q, leucine flux, C, leucine oxidation, S, leucin* 
synthesis 
clearance 
to protein, and MCR, leucine metabolic 
rate. 
of 
EPINEPHRINE/CORTISOL/GLUCAGON PROTOCOL 
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DISCUSSION 
We have shown that in response to a six hour infusion of 
cortisol to produce stress physiologic steroid levels, there is 
a 23% rise in total BCAA's, with a 40% rise in leucine, a 30% rise 
in isoleucine, and an 18% rise in valine. Other amino acids 
do not display significant changes in a consistent direction. 
These findings are in agreement with previous studies (111). 
There is no significant change in leucine enrichment over 
time. Assuming attainment of steady state, the flux of leucine 
is unchanged from the beginning of the study to the end. Thus 
to explain the increase in concentration of BCAA's we showed that 
the metabolic clearance rate for leucine falls by 30% (p< .005). 
Choice of pool size influences calculations of the rates of 
appearance and disappearance of leucine, but it seems that during 
the non-plateau period, R remains steady or falls slightly and 
3. 
that R^ falls somewhat more during the study. Cortisol also 
induced hyperglycemia (12%), which is consistent with previous 
findings (111). 
We have shown that infusion of cortisol, epinephrine, and 
glucagon together produces a significant fall in plasma levels 
of total BCAAs { 42%), leucine (45%), isoleucine (50%), valine (40%), 
as well as of threonine (47%), serine (48%), glycine (42%), 
tyrosine (50%), glutamine (20%), and phenylalanine (29%). 
Preliminary enrichment data from two patients indicate that 
leucine flux falls and metabolic clearance rate increases during 
the study. A 100% increase in plasma glucose levels was 
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induced by infusion of the three hormones. This is consistent 
with previously published studies (112, 113). Carbon dioxide 
production rose by 25%, and oxygen consumption rose by 25%. 
Hormonal levels achieved during the infusion were similar to 
those seen in acute stress situations, as described in the 
literature review. During both protocols, cortisol rose to 
approximately 40/^g/dl, and in the triple hormone infusion, 
glucagon rose to approximately 450 pg/ml and epinephrine to 
about 500 pg/ml. In the cortisol study these latter two hormones 
did not change significantly, nor did insulin levels change. 
In contrast, in the triple hormone infusion, insulin levels rose 
100% to approximately 25 ^U/ml. 
Thus in the present study physiological increments of cir¬ 
culating cortisol produced a selective increase in branched 
chain amino acid levels, and no consistent change in levels of 
other amino acids. These findings are consistent with previous 
results. To evaluate the mechanism for these changes we infused 
1-^C-leucine as tracer. This is a validated method; use of 
leucine labelled in the one-position is particularly desirable for 
reasons discussed in the literature review. This demonstrated a 
significant lowering of the metabolic clearance rate over time. 
If we assume a steady state plateau has been reached during the 
last hour of study (an assumption which our data suggest but do not 
confirm), then steady state kinetics show that leucine flux at the 
final "plateau" is not significantly different from that during .- 
the pre-infusion period. Since the concentration of leucine in 

70 
plasma rose quite significantly during the infusion period, it 
was postulated that there must have been a change in the rela¬ 
tive rates of appearance and disappearance of leucine. A rise 
in leucine concentration necessitates either a stable or falling 
R with a more extensively falling R , or a rise in R with a stable 
3 a a 
or falling or more slowly rising R^. 
Our leucine enrichment data serve to eliminate some of these 
options. They display no significant change in enrichment over 
the course of the study. For this to occur, there must be no 
significant change in R , since a change in R would have to be 
3 3 
due to a change in rate of appearance of unlabelled leucine from 
endogenous protein stores, because the rate of infusion of labelled 
leucine is, of course, held constant. If the rate of appearance 
of unlabelled leucine increases while appearance of label is 
held constant, then the enrichments would have to fall. This was 
clearly not the case; if anything, enrichments tended to rise. 
Thus to explain the significant rise in total leucine levels over 
the course of the study, the lack of significant change in enrich¬ 
ments suggests that there may have been a decrease in R , and no 
significant change in R . 
The above conclusions rest on the accuracy of determination 
of leucine enrichment, which may not be great enough to uncover 
small and gradually changing alterations in enrichments during 
the course of the study. 
To gain some insight into the mechanism by which subjects 
moved from the pre-infusion steady state to the final "plateau" 
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a single pool non-steady state model was used. It is difficult 
to determine precisely what pool fraction to apply to the data to 
correct for the volume of distribution of leucine in human beings. 
0.15 is the value commonly chosen for glucose, and represents the 
extracellular space. Yet we know that leucine is more extensively 
distributed than is glucose, and is found in intracellular space 
as well. Leucine dose not, however, distribute as freely as does 
waterj the factor applied for calculations of total body water is 
0.6. Thus the appropriate value is between 0.15 and 0.6. Using 
too large a value for the correction applied to leucine will 
increase the difference between R and R_, artificially, thus tend- 
a d 
ing to confirm the results which our enrichment data suggest. A 
too small value will perhaps minimize differences between the rates, 
as is seen in the calculations using 0.15, which hint that R^ has 
fallen somewhat, and that R^ has fallen to a greater extent than 
has R . These trends are more pronounced using the factor 0.45. 
Thus, although it is not possible to determine the accuracy of 
any one rate, it is reasonable to generalize from the trends which 
the calculations show. It is important to consider recycling of 
label. If this is extensive, it could mask an increase in R 
cl 
which could be occurring. 
As in previous studies in our laboratory, (111), plasma insu¬ 
lin levels were stable throughout the infusion of cortisol, despite 
cortisol-induced hyperglycemia. It has been postulated that cdrt- 
isol may suppress glucose-stimulated insulin release, at least in 
the acute phase. Chronic glucocorticoid excess, on the other hand. 
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does result in hyperinsulinemia. Alternatively, the lack of a 
rise in insulin may be due to the gradual increase in glucose 
levels. 
In a study of the effect of insulin on leucine kinetics in 
dogs (130), it has been found that insulin lack causes no change 
in rate of appearance of leucine, induces a decrease in its rate 
of disappearance, and a decrease in metabolic clearance rate, 
such that plasma leucine increases by 40% (p<.005). These 
results are similar in direction to the ones we obtained in our 
cortisol study, yet in our study there is no apparent drop in 
insulin levels. But it has been suggested (3reviously (111) that 
physiologic hypercortisolemia could antagonize the action of 
insulin on target tissues. Since these authors found no cortisol- 
induced change in insulin binding to monocytes, which could suggest 
that there was no change in insulin receptors in target tissues, 
their findings suggest that cortisol effects insulin's actions via 
a post-receptor mechanism. A study supporting this concept (131) 
showed that glucocorticoids induced inhibition of insulin-stimulated 
glucose transport in the absence of changes in insulin binding. 
Thus, perhaps there is a "perceived" insulin lack during out 
cortisol study which contributed to elevations of BCAAs despite 
the absence of changes in circulating plasma insulin levels. 
It is of interest to examine a preliminary study by Haymond ft cvl 
(132). To determine the effects of steroids on protein metabolism, 
they employed labelled leucine and alanine as tracers in subjects 
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receiving either saline or cortisol infusion. The latter 
resulted in plasma cortisol levels essentially the same as in 
our study. 
Their studies similarly induced no change in plasma insulin 
levels. Plasma leucine increased somewhat more than in our study. 
Haymond concluded that leucine R increased during cortisol infu- 
cl 
sion. as did leucine Rn. Alanine R and Rn also increased. The 
d d 
percent of alanine derived from leucine increased, and the percent 
of leucine going to alanine increased. These data for leucine R^ 
and R^ are in contrast to our findings. This could be a result of 
differences in labelling of tracer, in sampling site, or most-likely, 
aiR a result of imprecision of the techniques for measuring 
small variations. 
The small, gradual increase in plasma glucose levels in response 
to cortisol infusion was similar in our study to that demonstrated 
previously in Sherwin's laboratory (111). These authors showed, 
using a similar protocol, that the hyperglycemic response to cort¬ 
isol is due to a 30% (p <.005) decrease in glucose clearance. 
Glucose output actually tended to decline (0.1> p> .05), but 
glucose uptake fell more significantly (15%, p <.05). 
It is interesting that effects on substrate concentration, 
substrate clearance rate, rate of appearance and rate of disappear¬ 
ance of substrate in our study are similar in direction to those 
observed in the above study where glucose was examined as substrate 
under the same experimental conditions as we used to study leucine. 
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Comparison between the amino acid responses to our two 
protocols is of interest. Cortisol infusion produced a significant 
rise in leucine levels, while infusion of cortisol with epinephrine 
and glucagon produced a significant fall in leucine levels. This 
is in contrast to the synergistic effect of similar levels 
of the three hormones to produce changes in plasma glucose 
levels in the same direction as that which cortisol alone causes. 
Studies in our laboratory (113) in normal healthy volunteers 
demonstrated that individually, glucagon results in a transient 
rise in glucose production, cortisol produces a fall in glucose 
clearance, and epinephrine acts in both ways. When infused 
together, epinephrine and glucagon stimulate glucose overproduction, 
and cortisol sustains this effect. The accompanying hyperinsulinemia 
can not increase glucose disposal, because epinephrine and perhaps 
cortisol are suppressing glucose clearance. 
Studies looking at the effects of the three hormones 
individually on amino acid levels have been done. Our laboratory 
(111) showed that in five hours cortisol induces statistically 
significant elevations in plasma BCAAs, leucine, isoleucine and 
valine. 
Epinephrine, on the other hand, (133) caused a decline in 
circulating amino acids, with the exception of alanine, even in 
the absence of a rise in plasma insulin. In five hours, leucine, 
isoleucine, and valine fell. Total BCAAs thus fell by 40% in 
response to epinephrine. This effect was not blocked by -adren¬ 
ergic blockade. Thus epinephrine and insulin seem to have similar 
effects on amino acid metabolism. But studies in which similar 
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results were obtained with diabetic subjects indicated that the 
hyperaminoacidemic response to epinephrine was in part independent 
of changes in circulating insulin levels. 
Glucagon (134) infused for two hours into healthy subjects 
produced a significant rise in insulin levels and a significant fall 
in 15 of 18 measured amino acid levels, including the BCAAs. But 
diabetic men, who did not experience hyperinsulinemia, showed no 
change in BCAA levels. Thus it was concluded that glucagon appears 
to have no effect on BCAA levels. The diabetic subjects did show 
a fall in 10 of 18 amino acids, including all the major gluco¬ 
neogenic precursors. In another study (135) glucagon infusion 
in forearm tissue produced no change in muscle amino acid balance. 
BCAAs thus rise in response to cortisol, fall in response to 
epinephrine, and do not change in response to glucagon. There 
are no data in the literature on the amino acid response of 
healthy subjects to infusion of the hormones together. We have 
shown that BCAAs fall markedly in response to acute induction of 
stress levels of epinephrine, glucagon and cortisol. A plausible 
mechanism to explain this hypoaminoacidemic response implicates 
the hyperinsulinemia induced by the three hormones as a causative 
factor. It has been shown (130) that twice basal hyperinsulinemia 
produced a 36% drop in plasma leucine. R decreased by 15%, and 
<3. 
MCR increased by 56% in that study. Our kinetic data, although 
based so far on only two subjects, display similar trends. 
Enrichment data for the remaining subjects will hopefully lend 
significance to these trends. 
Epinephrine may also be contributing significantly to the 
hypoaminoacidemic response. It may very well work in concert 
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with insulin to overcome the effects of cortisol. 
In general, our triple hormone infusion protocol has demon¬ 
strated that experimentally, the body is better able -to prevent 
acute severe protein wasting in response to stress hormones than 
it is able to prevent glucose intolerance in such situations. 
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